# Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

> **NCT01907113** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 10773
- **DRUG:** BI 10773
- **DRUG:** BI 10773
- **DRUG:** BI 10773
- **DRUG:** BI 10773

## Key facts

- **NCT ID:** NCT01907113
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907113, "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01907113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*